The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer

  • End date
    Aug 3, 2021
  • participants needed
  • sponsor
    Dutch Colorectal Cancer Group
Updated on 3 February 2020
Dave E vanderKruijssen, MD
Primary Contact
St Annaziekenhuis (3.0 mi away) Contact
+51 other location
renal function
neutrophil count
liver metastasis
metastatic colon cancer


The clinical benefit of resection of the primary tumour in patients with synchronous unresectable metastases is not known. In the literature studies usually describe retrospective selected patients with synchronous metastases treated with or without resection of the primary tumour. All these studies are biased in patient selection and there are no prospective randomized studies on this topic. In patients with few or absent symptoms of the primary tumour, arguments both in favour and against initial resection have been presented, and therefore a randomized trial is warranted. Although recent publications suggest that resection of the primary tumour in synchronous metastasized colon cancer patients might not be necessary, this appears to be based on feasibility and not on clinical outcome. Several studies comparing large groups of patients with or without resection of the primary tumour suggest an improved survival when the primary tumour is resected. A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour during chemotherapy treatment or during later stages of the disease. A recent analysis of the CAIRO and CAIRO2 data showed that metastatic colon cancer patients who had a resection of the primary tumour prior to study entry, had an improved survival compared to patients without a resection of the primary tumour. However, these patients were selected after the primary tumour was resected and therefore these results are not corrected for surgical morbidity and mortality. The investigators here propose a randomized trial in order to demonstrate that resection of the primary tumour does improve overall survival.

Treatment Surgery of the primary tumour, Systemic treatment
Clinical Study IdentifierNCT01606098
SponsorDutch Colorectal Cancer Group
Last Modified on3 February 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Rectal Cancer or Primary Tumour or Colorectal Cancer or Colon Cancer or Colon Cancer Screening or Malignant neoplasm of colon or Colon cancer; rectal ...?
Histological proof of colorectal cancer
Resectable primary tumour in situ with unresectable distant metastases
No indication for neo-adjuvant (chemo)radiation
No severe signs or symptoms related to the primary tumour (i.e. severe bleeding, obstruction, severe abdominal pain) that require immediate surgery or other symptomatic treatment (e.g. stenting)
No prior systemic treatment for advanced disease
Age 18 years
WHO performance status 0-2
Laboratory values obtained 4 weeks prior to randomization: Adequate bone marrow function (Hb 6.0 mmol/L, absolute neutrophil count 1.5 x 109/L, platelets 100 x 109/L), renal function (serum creatinine 1.5x ULN and creatinine clearance, Cockroft formula, 30 ml/min), liver function (serum bilirubin 2 x ULN, serum transaminases 3 x ULN without presence of liver metastases or 5x ULN with presence of liver metastases)
Expected adequacy of follow-up
Written informed consent
CT scan abdomen and CT thorax/X-thorax performed 4 weeks prior to randomization

Exclusion Criteria

Pregnancy, lactation
Unresectable primary tumour (i.e. neurovascular encasement, substantial ingrowth in pancreatic head), or any condition preventing the safety or feasibility of resection of the primary tumour, i.e. massive ascites or extensive peritoneal disease
Requirement of neoadjuvant (chmo)radiation therapy
Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin
Any medical condition that prevents the safe administration of systemic treatment
Previous intolerance of fluoropyrimidines, known dihydropyrimidine dehydrogenase (DPD) deficiency
Planned radical resection of all metastatic disease
Uncontrolled hypertension, i.e. values consistently > 150/100 mmHg
Use of 3 antihypertensive drugs
Significant cardiovascular disease < 1 yr before randomization (symptomatic congestive heart failure, myocardial infarction, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, cerebro vascular event)
Chronic active infection
Concurrent treatment with any other anti-cancer therapy as described per protocol
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet